Cabaletta Bio

CABA

Market cap $168M

Overview Fund Activity

1.84 USD

+0.03

1.66%

At close Updated Sep 12, 4:00 PM EDT

Pre-market

After hours

1.85

+0.01

0.54%

1 day

1.66%

5 days

6.36%

1 month

38.35%

3 months

2.22%

6 months

-3.66%

Year to date

-21.03%

1 year

-54.34%

5 years

-84.68%

10 years

-81.6%

About: Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Employees: 167

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,087% more call options, than puts

Call options by funds: $1.8M | Put options by funds: $152K

120% more capital invested

Capital invested by funds: $50.3M [Q1] → $111M (+$60.4M) [Q2]

69.15% more ownership

Funds ownership: 74.27% [Q1] → 143.42% (+69.15%) [Q2]

5% less funds holding

Funds holding: 92 [Q1] → 87 (-5) [Q2]

16% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 32

18% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 28

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2

9% upside

Avg. target

$10.5

471% upside

High target

$15

715% upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Cantor Fitzgerald Josh Schimmer	$15	Overweight Reiterated	5 Sep 2025
Citigroup Samantha Semenkow	$10	Buy Maintained	14 Aug 2025
Wells Fargo Derek Archila	$2	Equal-Weight Maintained	8 Aug 2025
Guggenheim Yatin Suneja	$15	Buy Maintained	8 Aug 2025

See Analyst Rankings

Financial journalist opinion

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in September: Cantor Global Healthcare Conference 2025: Webcasted fireside chat at 10:55 a.m. ET on Wednesday, September 3, 2025, in New York, NY.

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Zacks Investment Research

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Cabaletta Bio (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

The Motley Fool

Cabaletta Bio (CABA) Q2 Loss Widens 30%

Cabaletta Bio (CABA) Q2 Loss Widens 30%

Cabaletta Bio (CABA) Q2 Loss Widens 30%

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis –

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

In May, FDA Commissioner Marty Makary named Vinay Prasad the next director of the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER). Within three months, Prasad resigned.

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Cabaletta Bio Announces Pricing of Public Offering of Securities

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced today the pricing of an underwritten public offering consisting of (i) 39,200,000 shares of its common stock and accompanying warrants to purchase an aggregate of 39,200,000 shares of common stock (or pre-funded warrants in lieu thereof) and (ii) in lieu of common stock, to certain investors, pre-funded warrants to purchase an aggregate of up to 10,800,000 shares of its common stock and accompanying warrants to purchase an aggregate of 10,800,000 shares of common stock (or pre-funded warrants in lieu thereof), at an exercise price of $0.00001 per pre-funded warrant. Cabaletta also granted the underwriters a 30-day option to purchase up to an additional 15,000,000 shares of common stock and/or warrants at the public offering price, less underwriting discounts and commissions. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock (or a pre-funded warrant in lieu thereof) issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $2.50 per share, is immediately exercisable from the date of issuance and will expire fifteen months from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $1.99999.

Cabaletta Bio Announces Pricing of Public Offering of Securities

Cabaletta Bio: Sector Headwinds And Funding Issues

Cabaletta Bio's CAR T-cell therapy shows durable efficacy in autoimmune diseases, with manageable side effects and promising early clinical data updates. The company plans a BLA submission for myositis in 2027, supported by FDA's RMAT designation and a focused clinical trial strategy. Financial risk is significant: current cash plus a new offering extends runway only modestly, likely insufficient to reach commercialization without further dilution.

Cabaletta Bio: Sector Headwinds And Funding Issues

Cabaletta Bio Announces Proposed Public Offering of Securities

PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). Cabaletta also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and warrants offered in the public offering. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Cabaletta.

Cabaletta Bio Announces Proposed Public Offering of Securities

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding patients –

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY.

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

See News Rankings

Charts implemented using Lightweight Charts™